Hainan Huluwa Pharmaceutical Group Co Ltd (605199) - Net Assets
Based on the latest financial reports, Hainan Huluwa Pharmaceutical Group Co Ltd (605199) has net assets worth CN¥429.55 Million CNY (≈ $62.86 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.56 Billion ≈ $374.03 Million USD) and total liabilities (CN¥2.13 Billion ≈ $311.18 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset allocation strategy of Hainan Huluwa Pharmaceutical Group Co Lt to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥429.55 Million |
| % of Total Assets | 16.81% |
| Annual Growth Rate | 15.15% |
| 5-Year Change | -50.78% |
| 10-Year Change | N/A |
| Growth Volatility | 60.9 |
Hainan Huluwa Pharmaceutical Group Co Ltd - Net Assets Trend (2016–2025)
This chart illustrates how Hainan Huluwa Pharmaceutical Group Co Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see market value of Hainan Huluwa Pharmaceutical Group Co Lt.
Annual Net Assets for Hainan Huluwa Pharmaceutical Group Co Ltd (2016–2025)
The table below shows the annual net assets of Hainan Huluwa Pharmaceutical Group Co Ltd from 2016 to 2025. Also explore Hainan Huluwa Pharmaceutical Group Co Lt annual equity growth to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥458.02 Million ≈ $67.02 Million |
-38.38% |
| 2024-12-31 | CN¥743.28 Million ≈ $108.77 Million |
-35.89% |
| 2023-12-31 | CN¥1.16 Billion ≈ $169.65 Million |
+14.19% |
| 2022-12-31 | CN¥1.02 Billion ≈ $148.57 Million |
+9.11% |
| 2021-12-31 | CN¥930.52 Million ≈ $136.16 Million |
+1.53% |
| 2020-12-31 | CN¥916.48 Million ≈ $134.11 Million |
+42.32% |
| 2019-12-31 | CN¥643.94 Million ≈ $94.23 Million |
+6.50% |
| 2018-12-31 | CN¥604.61 Million ≈ $88.47 Million |
+72.07% |
| 2017-12-31 | CN¥351.38 Million ≈ $51.42 Million |
+173.04% |
| 2016-12-31 | CN¥128.69 Million ≈ $18.83 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Hainan Huluwa Pharmaceutical Group Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3605.2% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CN¥748.62 Million | 181.39% |
| Total Equity | CN¥412.70 Million | 100.00% |
Hainan Huluwa Pharmaceutical Group Co Ltd Competitors by Market Cap
The table below lists competitors of Hainan Huluwa Pharmaceutical Group Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Lifezone Metals Limited
NYSE:LZM
|
$340.78 Million |
|
Borosil Limited
NSE:BOROLTD
|
$340.87 Million |
|
Jiangsu Jinling Sports Equipment Co Ltd
SHE:300651
|
$340.95 Million |
|
Waskita Karya Persero Tbk
JK:WSKT
|
$340.97 Million |
|
Regal Asian Investments Ltd
AU:RG8
|
$340.67 Million |
|
Companhia Energética do Ceará - Coelce
SA:COCE3
|
$340.55 Million |
|
DiaMedica Therapeutics Inc
NASDAQ:DMAC
|
$340.54 Million |
|
Zhejiang Tuna Environmental Science & Technology Co Ltd
SHG:603177
|
$340.33 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hainan Huluwa Pharmaceutical Group Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 700,553,123 to 412,703,353, a change of -287,849,770 (-41.1%).
- Net loss of 287,373,916 reduced equity.
- Dividend payments of 33,553,912 reduced retained earnings.
- Other comprehensive income decreased equity by 64,897,765.
- Other factors increased equity by 97,975,823.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-287.37 Million | -69.63% |
| Dividends Paid | CN¥33.55 Million | -8.13% |
| Other Comprehensive Income | CN¥-64.90 Million | -15.73% |
| Other Changes | CN¥97.98 Million | +23.74% |
| Total Change | CN¥- | -41.09% |
Book Value vs Market Value Analysis
This analysis compares Hainan Huluwa Pharmaceutical Group Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.64x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 7.27x to 5.64x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | CN¥0.80 | CN¥5.82 | x |
| 2017-12-31 | CN¥2.00 | CN¥5.82 | x |
| 2018-12-31 | CN¥1.86 | CN¥5.82 | x |
| 2019-12-31 | CN¥1.77 | CN¥5.82 | x |
| 2020-12-31 | CN¥2.41 | CN¥5.82 | x |
| 2021-12-31 | CN¥2.32 | CN¥5.82 | x |
| 2022-12-31 | CN¥2.48 | CN¥5.82 | x |
| 2023-12-31 | CN¥3.10 | CN¥5.82 | x |
| 2024-12-31 | CN¥1.76 | CN¥5.82 | x |
| 2025-12-31 | CN¥1.03 | CN¥5.82 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hainan Huluwa Pharmaceutical Group Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -69.63%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -31.90%
- • Asset Turnover: 0.35x
- • Equity Multiplier: 6.31x
- Recent ROE (-69.63%) is below the historical average (-1.05%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 26.24% | 6.93% | 0.91x | 4.16x | CN¥20.89 Million |
| 2017 | 6.30% | 3.38% | 0.81x | 2.30x | CN¥-13.01 Million |
| 2018 | 16.63% | 10.22% | 0.90x | 1.81x | CN¥40.08 Million |
| 2019 | 18.69% | 9.21% | 1.20x | 1.69x | CN¥55.94 Million |
| 2020 | 13.26% | 10.46% | 0.76x | 1.66x | CN¥29.85 Million |
| 2021 | 7.77% | 5.33% | 0.77x | 1.90x | CN¥-20.68 Million |
| 2022 | 8.45% | 5.66% | 0.66x | 2.28x | CN¥-15.71 Million |
| 2023 | 0.97% | 0.60% | 0.59x | 2.73x | CN¥-101.19 Million |
| 2024 | -39.18% | -19.42% | 0.48x | 4.23x | CN¥-344.51 Million |
| 2025 | -69.63% | -31.90% | 0.35x | 6.31x | CN¥-328.64 Million |
Industry Comparison
This section compares Hainan Huluwa Pharmaceutical Group Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,877,324,223
- Average return on equity (ROE) among peers: 8.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hainan Huluwa Pharmaceutical Group Co Ltd (605199) | CN¥429.55 Million | 26.24% | 4.95x | $340.75 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $1.78 Billion | 1.33% | 4.40x | $589.07 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.56 Billion | 7.90% | 1.45x | $422.95 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $2.46 Billion | 15.95% | 0.27x | $4.31 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $1.17 Billion | 10.59% | 0.88x | $2.30 Billion |
| Wedge Industrial Co Ltd (000534) | $1.41 Billion | 5.42% | 0.68x | $1.73 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $32.60 Million | 12.25% | 0.82x | $13.40 Billion |
| Hainan Haiyao Co Ltd (000566) | $2.54 Billion | 7.70% | 0.92x | $945.43 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $380.02 Million | 7.98% | 0.67x | $320.64 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $3.92 Billion | 4.44% | 2.20x | $1.01 Billion |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $23.53 Billion | 7.26% | 0.16x | $3.11 Billion |
About Hainan Huluwa Pharmaceutical Group Co Ltd
Hainan Huluwa Pharmaceutical Group Co., Ltd. research, develops, produces, and sells drugs in the areas of Children's digestive system, respiratory system, anti-infection, anti-virus and other fields in China. The company offers pediatrics, gynecology, antibiotics, respiratory, digestive system, cardiovascular and cerebrovascular, nourishment, and other medicine products. Hainan Huluwa Pharmaceut… Read more